Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML

Centre Hospitalier Régional Metz-Thionville

Overview

Advanced Practice Nurse (APN) is a new contributor in the French healthcare system. APN is part of a multidisciplinary team and aim to monitor patients under the coordination of the doctor particularly in onco-hematology. The aim of the study is to describe the different perceptions and expectations of APN monitoring according to patients with acute myeloid leukemia (AML) and their care team. This study will involve 10 patients, recruited over a provisional period of 5 months and 25 member of care team. Patients and their care team will be asked about their perceptions and expectations of APN participation in (AML monitoring) during a semi-structured interviews.

Study Type

OBSERVATIONAL

Conditions

Myeloid Leukemia

Interventions

InterviewsOTHER

Semi-structured interview about perceptions and expectations of APN participation in AML monitoring according to patient and to care team.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with AML * Treated with a new targeted oral therapy as monotherapy or in combination: * Venetoclax\* in combination with ivosidenib (IDH1 inhibitor) * Onureg\* (azacitin: pyrimidine analogue) * Venetoclax (BCL-2 protein inhibitor) in combination with subcutaneous azacitin * Whose follow-up is provided alternately by a hematologist and an IPA. * Affiliated to a social security scheme Exclusion Criteria: * Moderate or severe cognitive impairment * Language barrier * Other communication disorders

Outcomes

Primary Outcomes

Perception of patient

Semi-structured interview about perceptions and expectations of Advanced Practice Nurse (APN) participation in acute myeloid leukemia (AML) monitoring according to patient.

Time frame: Within 1 month

Secondary Outcomes

Perception of care team

Semi-structured interview about perceptions and expectations of Advanced Practice Nurse (APN) participation in acute myeloid leukemia (AML) monitoring according to care team.

Time frame: Within 1 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.